Search research articles
Contact Us
Filters
Showing results (451-460 of 464) with videos related to
Page
of 47
Sort By:
Journal of Medicinal Chemistry
|
February 20, 2019
Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1α Kinase-Endoribonuclease
Giampiero Colombano, John J Caldwell, Thomas P Matthews, et al.
Cancer Research
|
January 4, 2019
Correction: <i>In vitro</i> Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors
Swee Y Sharp, Kathy Boxall, Martin Rowlands, et al.
Blood
|
June 24, 2004
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine
Kenneth F Bradstock, Jane P Matthews, Raymond M Lowenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs
Mike I Walton, Paul D Eve, Angela Hayes, et al.
Microbial Drug Resistance (Larchmont, N.Y.)
|
January 6, 2001
Molecular typing of methicillin-resistant Staphylococcus aureus by pulsed-field gel electrophoresis: comparison of results obtained in a multilaboratory effort using identical protocols and MRSA strains
M Chung, H de Lencastre, P Matthews, et al.
Health Physics
|
August 2, 2012
Electron paramagnetic resonance dosimetry for a large-scale radiation incident
Harold M Swartz, Ann Barry Flood, Benjamin B Williams, et al.
Nature Genetics
|
March 2, 2010
Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization
Andrew R Cullinane, Anna Straatman-Iwanowska, Andreas Zaucker, et al.
Oncotarget
|
August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma
Mike I Walton, Paul D Eve, Angela Hayes, et al.
Molecular Cancer Therapeutics
|
April 14, 2007
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
Swee Y Sharp, Chrisostomos Prodromou, Kathy Boxall, et al.
Faraday Discussions
|
October 3, 2024
New directions in experiment and theory, interfaces, and interactions: general discussion
Rob Atkin, Duncan W Bruce, Robert A W Dryfe, et al.
Page
of 47
Search research articles
Search
Showing results (451-460 of 464) with videos related to
Sort By:
Page
of 47
Journal of Medicinal Chemistry
|
February 20, 2019
Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1α Kinase-Endoribonuclease
Giampiero Colombano, John J Caldwell, Thomas P Matthews, et al.
Cancer Research
|
January 4, 2019
Correction: <i>In vitro</i> Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors
Swee Y Sharp, Kathy Boxall, Martin Rowlands, et al.
Blood
|
June 24, 2004
A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine
Kenneth F Bradstock, Jane P Matthews, Raymond M Lowenthal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 30, 2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs
Mike I Walton, Paul D Eve, Angela Hayes, et al.
Microbial Drug Resistance (Larchmont, N.Y.)
|
January 6, 2001
Molecular typing of methicillin-resistant Staphylococcus aureus by pulsed-field gel electrophoresis: comparison of results obtained in a multilaboratory effort using identical protocols and MRSA strains
M Chung, H de Lencastre, P Matthews, et al.
Health Physics
|
August 2, 2012
Electron paramagnetic resonance dosimetry for a large-scale radiation incident
Harold M Swartz, Ann Barry Flood, Benjamin B Williams, et al.
Nature Genetics
|
March 2, 2010
Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization
Andrew R Cullinane, Anna Straatman-Iwanowska, Andreas Zaucker, et al.
Oncotarget
|
August 22, 2015
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma
Mike I Walton, Paul D Eve, Angela Hayes, et al.
Molecular Cancer Therapeutics
|
April 14, 2007
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
Swee Y Sharp, Chrisostomos Prodromou, Kathy Boxall, et al.
Faraday Discussions
|
October 3, 2024
New directions in experiment and theory, interfaces, and interactions: general discussion
Rob Atkin, Duncan W Bruce, Robert A W Dryfe, et al.
Page
of 47